Bayer and Onyx Announce Nexavar® (sorafenib tosylate) Tablets as Global Trade Name for Investigational Cancer Treatment
Bayer and Onyx filed a New Drug Application (NDA) in July 2005 requesting approval in advanced renal cell cancer by the U.S. Food and Drug Administration (FDA). Subsequently, the FDA granted the Nexavar filing priority review status, which means the FDA intends to make a determination within six months of when they received the NDA. Additionally in September 2005, a Marketing Authorization Application (MAA) was submitted to the European Medicines Agency (EMEA) to market Nexavar in Europe. If approved, Nexavar will be marketed by Bayer and Onyx through a co-promotion and co-development agreement.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.